165 related articles for article (PubMed ID: 24214101)
1. Demand for prescription drugs under non-linear pricing in Medicare Part D.
Jung K; Feldman R; McBean AM
Int J Health Care Finance Econ; 2014 Mar; 14(1):19-40. PubMed ID: 24214101
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D.
Jung K; Feldman R; McBean AM
Health Serv Res; 2014 Jun; 49(3):910-28. PubMed ID: 24354765
[TBL] [Abstract][Full Text] [Related]
3. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
Bonakdar Tehrani A; Cunningham PJ
Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
[TBL] [Abstract][Full Text] [Related]
4. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
5. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
6. Anticipatory Behavior in Response to Medicare Part D's Coverage Gap.
Kaplan CM; Zhang Y
Health Econ; 2017 Mar; 26(3):338-351. PubMed ID: 26749399
[TBL] [Abstract][Full Text] [Related]
7. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
9. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
10. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.
Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP
Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168
[TBL] [Abstract][Full Text] [Related]
11. Digesting the doughnut hole.
Joyce GF; Zissimopoulos J; Goldman DP
J Health Econ; 2013 Dec; 32(6):1345-55. PubMed ID: 24308883
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
13. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
14. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
[TBL] [Abstract][Full Text] [Related]
15. Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2018 Jul; 37(7):1048-1056. PubMed ID: 29985706
[TBL] [Abstract][Full Text] [Related]
16. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
[TBL] [Abstract][Full Text] [Related]
17. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
19. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
20. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
